Phase 1 Dose-Escalation Study Of A Novel Oral Pi3k/Mtor Dual Inhibitor, Ly3023414, In Patients With Cancer (Vol 46, Pg 837, 2020)

The article Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer, written by Shunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, Koichi Inoue, Hiroya Asou, Vinay Kumar Ranka, Volker Wacheck, Toshihiko Doi, was originally published electronically on the publisher's internet portal on 23 June 2020 without open access.